Objective: The aim of this study was to assess the efficacy and acceptability of cannabinoids for the treatment of anxiety disorders.
Methods: For this systematic review and meta-analysis, we searched for randomized trials utilizing cannabinoids for the treatment of adults with anxiety disorders. Primary outcomes were reduction in anxiety disorder symptoms, and study discontinuation due to adverse events. Evidence was synthesized as rate ratios (RRs) and as standardized mean differences (SMDs) using random-effects meta-analyses.
Results: A total of 14 eligible trials representing 1548 individuals (median age: 33 years; range: 28-44; 66% male) were identified. Cannabinoids reduced anxiety symptoms (SMD = -1.85, 95% CI: -2.61 to -1.09) without causing significant adverse events. Greater efficacy was observed among younger patients (p < 0.01) and with longer treatment (p < 0.01). However, publication bias was substantial, and after correction, the overall anxiolytic effect was not statistically significant.
Conclusions: While cannabinoids may be of potential value in the treatment of anxiety disorders, the routine use of these treatments is not supported by the available evidence after correction for publication bias.
Copyright © 2020. Published by Elsevier Ltd.